INM

Dopo l'orario di chiusura: 1.33 -0.05 -3.62%

Inmed Pharmaceuticals Inc (INM)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Inmed Pharmaceuticals Inc Stock (INM) Company Profile

Inmed Pharmaceuticals Inc

Healthcare (1067)

(604) 669-7207

1445-885 WEST GEORGIA ST., VANCOUVER

Prossima data di guadagno

Ultimi documenti SEC

INM's Discussions on Twitter

Compare INM vs TAK, TEVA, HLN, ZTS, VTRS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INM Inmed Pharmaceuticals Inc	1.38	7.58M	3.25M	-8.34M	-7.71M	-2.5755
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie

Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc Stock (INM) Company Profile

Compare INM vs TAK, TEVA, HLN, ZTS, VTRS

Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET - TMX Newsfile

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - TMX Newsfile

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules - TMX Newsfile

InMed Pharmaceuticals (INM) Faces Nasdaq Equity Shortfall Amid I - GuruFocus

Form 8K INMED PHARMACEUTICALS INC. For: 18 September By Investing.com - Investing.com Nigeria

InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

InMed Faces Nasdaq Equity Shortfall but Banks on Mentari Merger to Regain Compliance - TipRanks

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - TMX Newsfile

10% owner adds to InMed Pharmaceuticals (INM) stake with open-market buys - Stock Titan

InMed Reports FY2026 Net Loss Of $12.9 Million As Mentari Merger Advances With $490 Million Financing - Pulse 2.0

InMed winds down only revenue-generating business BayMedica - Minichart

GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView

[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC FilingForm S-4/A - Stock Titan

$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan

About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - TMX Newsfile

InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research

InMed (INM) Earnings Update: The Company Publishes Its Latest Results in the Latest Session; Price Reaction: Shares Close 7.59% Lower for the Current SessionPre-Earnings Setup - dars.gov.et

InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotIntraday Profile - vinanet.vn

InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Growth Forecast - vinanet.vn

InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeVolatility Skew - vinanet.vn

InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainCash Secured Put - vinanet.vn

INM Q3 2025 Earnings: Net Loss of $1.94 Per Share; Stock Rises 2.8%One-Time Gain Impact - vinanet.vn

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares - Stock Titan

Inmed Pharmaceuticals Stock Price Forecast. Should You Buy INM? - StockInvest.us

INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Biopharmaceutical InvestmentRevenue Breakdown Analysis - vinanet.vn

INM Q3 2025 Earnings: Net Loss of $1.94 Per Share ReportedFinancial Data - Vinanet

InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportMA Crossover - dars.gov.et

InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

InMed Pharmaceuticals (INM) Slips 6% to $1.40 as Support Level Comes into FocusCalendar Spread Trade - careplusvn.com

InMed Pharmaceuticals (INM) Rises 2.40% as Shares Approach Key $1.58 ResistanceSMA Signal - careplusvn.com

INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Clinical InvestmentEarnings Per Share - careplusvn.com

INM Q3 2025 Earnings: Narrowing Losses and Cautious Pipeline ProgressRevenue Growth Report - vinanet.vn

InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey

INM|InMed Pharmaceuticals Inc|Price:1.580|Chg%:-0.130 - TradingKey

TradingKey - TradingKey

INM|InMed Pharmaceuticals Inc|Price:1.670|Chg%:-0.040 - TradingKey

InMed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:INM - TradingView

InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

ADAR1 Capital Management, LLC Acquires Additional Shares in InMed Pharmaceuticals Inc - GuruFocus

INM Q3 2025 Earnings: InMed Pharmaceuticals Reports Net Loss of $1.94 Per Share as Stock Rises 11.45%Guidance Accuracy Score - dars.gov.et

Mentari Therapeutics Raises $200 Million for Migraine Prevention Pipeline Ahead of InMed Merger - Minichart

InMed Pharmaceuticals (INM) plans Mentari merger with $490M financings - Stock Titan

InMed to Merge with Mentari as Mentari Secures $200M Pre-Closing Financing - TradingView

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - Benzinga

Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a INM